#1 Clinical Trials Search in Europe

Pertuzumab

This article examines the use of pertuzumab, a targeted cancer drug, in various clinical trials. Pertuzumab is being studied for its effectiveness and safety in treating different types of cancer, particularly breast cancer and prostate cancer. The trials aim to evaluate how well pertuzumab works alone or in combination with other treatments, its side effects, and how patients’ bodies process the drug.

Table of Contents

What is Pertuzumab?

Pertuzumab is a medication used in the treatment of certain types of breast cancer. It’s known by the brand name Perjeta[1]. Pertuzumab is a type of drug called a monoclonal antibody, which is a laboratory-made protein that mimics the immune system’s ability to fight off harmful antigens such as cancer cells[1].

This drug is specifically designed to target and block a protein called HER2 (Human Epidermal Growth Factor Receptor 2), which is found in high amounts on the surface of some cancer cells[1]. When HER2 is present in high amounts, it can make cancer cells grow and divide more quickly.

How Pertuzumab Works

Pertuzumab works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When pertuzumab attaches to these receptors, it blocks the signals that tell the cells to grow. This process helps to slow or stop the growth of the breast cancer[1].

Additionally, by attaching to the HER2 receptors, pertuzumab may mark the cancer cell for destruction by your immune system. This dual action of blocking growth signals and potentially activating the immune system makes pertuzumab an effective treatment for HER2-positive breast cancers[1].

Conditions Treated with Pertuzumab

Pertuzumab is primarily used to treat:

  • HER2-positive metastatic breast cancer: This is breast cancer that has spread to other parts of the body and has high levels of the HER2 protein[1].
  • Early-stage HER2-positive breast cancer: Pertuzumab can be used as part of treatment before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy) for early-stage breast cancer[2].
  • Locally advanced HER2-positive breast cancer: This is breast cancer that has spread to nearby tissues or lymph nodes but not to distant parts of the body[2].
  • Central Nervous System Metastases: Some studies are exploring the use of pertuzumab in treating breast cancer that has spread to the brain[1].

How Pertuzumab is Administered

Pertuzumab is typically administered through intravenous (IV) infusion, which means it’s given directly into your vein. The usual dosing schedule is:

  • An initial loading dose of 840 mg[2].
  • Followed by maintenance doses of 420 mg every 3 weeks[2].

The infusion usually takes about 30-60 minutes. Your healthcare team will monitor you during and after the infusion for any side effects or reactions[3].

Pertuzumab in Combination Therapy

Pertuzumab is often used in combination with other cancer treatments to enhance its effectiveness. Common combinations include:

  • Pertuzumab + Trastuzumab + Docetaxel: This combination is often used for metastatic HER2-positive breast cancer. Trastuzumab (brand name Herceptin) is another HER2-targeted therapy, while docetaxel is a type of chemotherapy[4].
  • Pertuzumab + Trastuzumab + Chemotherapy: This combination is used in the neoadjuvant (before surgery) setting for early-stage or locally advanced HER2-positive breast cancer[2].

These combinations target the cancer in multiple ways, potentially improving outcomes for patients.

Clinical Studies and Efficacy

Several clinical studies have demonstrated the effectiveness of pertuzumab:

  • In metastatic HER2-positive breast cancer, the combination of pertuzumab, trastuzumab, and docetaxel has shown improved progression-free survival compared to trastuzumab and docetaxel alone[4].
  • In the neoadjuvant setting, adding pertuzumab to trastuzumab and chemotherapy has increased the rates of pathological complete response (pCR), which means no detectable cancer in the breast or lymph nodes after treatment[2].
  • Some studies are exploring the use of pertuzumab in treating breast cancer that has spread to the brain, with promising early results[1].

Safety and Side Effects

Like all medications, pertuzumab can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea
  • Fatigue
  • Rash
  • Decreased appetite

More serious side effects, though less common, can include:

  • Heart problems
  • Severe allergic reactions
  • Fetal harm if used during pregnancy

Your healthcare team will monitor you closely for any side effects and can help manage them if they occur[5].

Ongoing Research and Future Directions

Research on pertuzumab is ongoing, with several studies exploring its use in different settings and combinations:

  • Short-course therapy: Some studies are investigating whether a shorter course of pertuzumab (e.g., 4 cycles) combined with other treatments can be as effective as longer treatments while reducing side effects[6].
  • Biosimilars: Researchers are developing and testing biosimilar versions of pertuzumab, which could potentially increase access to this treatment[7][2].
  • New combinations: Studies are exploring pertuzumab in combination with other targeted therapies and immunotherapies to potentially improve outcomes further[1].

These ongoing studies aim to optimize the use of pertuzumab, potentially expanding its benefits to more patients with HER2-positive breast cancer.

Aspect Details
Main Cancer Types Studied HER2-positive breast cancer, Prostate cancer
Common Dosage 420 mg every 3 weeks, often with 840 mg loading dose
Administration Method Intravenous (IV) infusion
Key Study Objectives Efficacy, Safety, Pharmacokinetics, Comparison with existing treatments
Combination Therapies Often combined with trastuzumab, docetaxel, or other chemotherapy drugs
Primary Outcomes Measured Pathological complete response, Progression-free survival, Overall survival
Safety Monitoring Adverse events, Immunogenicity, Vital signs, Laboratory tests
Pharmacokinetic Parameters AUC, Cmax, Half-life, Clearance, Volume of distribution

FAQ

  • What is pertuzumab? Pertuzumab is a targeted cancer drug that belongs to a class of medications called monoclonal antibodies. It works by attaching to and blocking a specific protein called HER2 on cancer cells, which can help slow or stop cancer growth.
  • What types of cancer is pertuzumab being studied for? Based on the clinical trials data, pertuzumab is primarily being studied for HER2-positive breast cancer, including early-stage, locally advanced, and metastatic forms. It is also being investigated for use in prostate cancer.
  • How is pertuzumab administered in these trials? In most trials, pertuzumab is given as an intravenous (IV) infusion. The typical dose is 420 mg every 3 weeks, often with a higher initial loading dose of 840 mg. Some trials are exploring different dosing regimens.
  • What are the main goals of these clinical trials? The main goals include assessing the effectiveness of pertuzumab in treating cancer, evaluating its safety and side effects, studying how the body processes the drug (pharmacokinetics), and comparing pertuzumab to existing treatments or potential biosimilar versions.
  • Are there any common side effects of pertuzumab observed in these trials? While specific side effects aren't detailed in the provided data, the trials are monitoring for adverse events. Common side effects of pertuzumab can include diarrhea, hair loss, nausea, fatigue, rash, and potential heart-related issues. However, each patient's experience may vary.

Ongoing Clinical Trials on Pertuzumab

  • Study of oral TherO2-01S22 with anti-HER2 therapy in patients with metastatic breast cancer

    Not yet recruiting

    4 1 1
    Investigated drugs:
    France

  • Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Germany Italy Romania Spain

  • Study on the Effectiveness of Trastuzumab, Pertuzumab, and Docetaxel for Patients with Early HER2-Positive Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Sweden

  • Study of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Personalized Treatment for High-Risk Breast Cancer Using Palbociclib, Olaparib, and Pertuzumab in Patients with Advanced Disease

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Italy Spain

  • Study on the Effects of Atezolizumab, Trastuzumab, and Pertuzumab in Patients with Early-Stage Triple-Negative or HER2+ Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany Italy Poland Spain

  • Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Portugal Spain

  • Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • HER2: Human Epidermal Growth Factor Receptor 2, a protein that promotes the growth of cancer cells. Some breast cancers have higher levels of HER2 and are called HER2-positive.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In cancer treatment, monoclonal antibodies can be used to deliver drugs directly to cancer cells.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually before surgery, to shrink a tumor or slow the cancer's growth.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Biosimilar: A biological product that is highly similar to an already approved biological product, with no clinically meaningful differences in terms of safety and effectiveness.
  • Pathological complete response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with cancer drugs.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment based on whether tumors shrink, stay the same, or get bigger.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland. PSA levels in the blood can be elevated in men with prostate cancer and are often used to monitor the disease.

References

  1. https://clinicaltrials.gov/study/NCT03417544
  2. https://clinicaltrials.gov/study/NCT05346224
  3. https://clinicaltrials.gov/study/NCT05471648
  4. https://clinicaltrials.gov/study/NCT01276041
  5. https://clinicaltrials.gov/study/NCT02266173
  6. https://clinicaltrials.gov/study/NCT05891561
  7. https://clinicaltrials.gov/study/NCT05738993